EPBIO
EP BIOCOMPOSITES financials
- Market cap
- ₹17 Cr
Quarterly results
Q4 FY26: revenue up 35.9%, net profit up 47.3% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 4 | 4 | 7 | 4 +28% | 8 +107% | 4 −8% | 10 +36% |
| EBITDA | 1 | 0 | 0 | 1 | 0 −8% | 1 +207% | 0 −4% | 2 +75% |
| Net profit | 0 | 0 | 0 | 1 | 0 −22% | 1 +177% | 0 −59% | 1 +47% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −20.4% 1Y
1Y: ₹133 on 5 Sept 2025 → ₹105.85. High ₹149.9 (21 Oct 2025), low ₹84 (30 Mar 2026).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Reserves | ₹0 Cr | ₹1 Cr | ₹7 Cr | ₹8 Cr | ₹9 Cr | ₹10 Cr |
| Borrowings | ₹0 Cr | ₹4 Cr | ₹1 Cr | ₹2 Cr | ₹4 Cr | ₹2 Cr |
| Other liabilities | ₹1 Cr | ₹3 Cr | ₹2 Cr | ₹4 Cr | ₹1 Cr | ₹4 Cr |
| Total liabilities | ₹1 Cr | ₹9 Cr | ₹12 Cr | ₹15 Cr | ₹16 Cr | ₹19 Cr |
| Fixed assets | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹1 Cr | ₹9 Cr | ₹11 Cr | ₹15 Cr | ₹15 Cr | ₹18 Cr |
| Total assets | ₹1 Cr | ₹9 Cr | ₹12 Cr | ₹15 Cr | ₹16 Cr | ₹19 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 10% to 337.
- Promoters
- 70.1%
- Public
- 29.9%
Since Jun 2025
- Public −0.01 pp
- Promoters 0.00 pp
- FIIs 0.00 pp
How it drifted, 12 quarters
Over this window FIIs fell from 2.2% to 0.0% — −2.2 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 70.1%, FIIs 2.2%, Public 27.7%.Dec '23: Promoters 70.1%, FIIs 2.2%, Public 27.7%.Mar '24: Promoters 70.1%, FIIs 2.2%, Public 27.7%.Jun '24: Promoters 70.1%, Public 29.9%.Sep '24: Promoters 70.1%, Public 29.9%.Dec '24: Promoters 70.1%, Public 29.9%.Mar '25: Promoters 70.1%, Public 29.9%.Jun '25: Promoters 70.1%, Public 29.9%.Sep '25: Promoters 70.0%, Public 29.9%.Dec '25: Promoters 70.1%, Public 29.9%.Mar '26: Promoters 70.1%, Public 29.9%.Jun '26: Promoters 70.1%, Public 29.9%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Kavita Kumar Santosh +0.18 pp 2.26% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of EP BIOCOMPOSITES LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Leena Rajkumar Kamat . | 64.93% | unchanged |
| Rajkumar Gajanan Kamat | 3.99% | unchanged |
| Kavita Kumar Santosh | 2.26% | +0.18 pp |
| Sambhav Dawar | 1.61% | unchanged |
| Rajiv Mehta | 1.31% | unchanged |
| Nimisha Rajkumar Kamat | 0.84% | unchanged |
| Ashma Rajkumar Kamat . | 0.31% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse EP BIOCOMPOSITES LIMITED
Guides on how to read this kind of business and the numbers that matter.